NovaBridge Biosciences

NovaBridge Biosciences is a global biotechnology platform company dedicated to accelerating access to innovative medicines. The company integrates deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Headquartered in Rockville, Maryland, NovaBridge Biosciences also maintains operations in Short Hills, New Jersey, and has a global presence with offices in Boston, Hong Kong, and Shanghai.

The company's core business focuses on developing therapies in immuno-oncology and ophthalmology. Its pipeline includes several clinical-stage programs such as Givastomig, a CLDN18.2 x 4-1BB bispecific antibody targeting gastric cancer; Ragistomig, a PD-L1 x 4-1BB bispecific antibody for solid tumors; and Uliledlimab, an anti-CD73 monoclonal antibody for non-small cell lung cancer (NSCLC). Through its subsidiary, Visara, Inc., NovaBridge Biosciences is also developing VIS-101, a VEGF-A/ANG2 bispecific antibody for retinal vascular diseases like wet age-related macular degeneration (AMD).

NovaBridge Biosciences underwent a significant corporate transformation in October 2025, changing its name from I-Mab and commencing trading on Nasdaq under the new ticker symbol NBP. This rebranding reflects its strategic shift to a global biotechnology platform utilizing a "hub-and-spoke" model to bring innovative medicines to worldwide markets. The leadership team includes Dr. Xi-Yong Fu as CEO, Wei Fu as Executive Chairman, and Mark Hagler, who was appointed President and Chief Commercial Officer in April 2026.